Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Ann Hematol Retrieve available abstracts of 350 articles: HTML format

Single Articles

September 2025
1. LI J, Yuan Y, Niu FF, Wang Y, et al
   USP7 mutations are associated with adverse outcomes in pediatric T cell acute lymphoblastic leukemia and lymphoma.
   Ann Hematol. 2025 Sep 22. doi: 10.1007/s00277-025-06582.
   PubMed     Abstract available
   
   
   
2. RANTI J, Jamalzadeh S, Makela E, Vikkula J, et al
   Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013-2022 in Finland.
   Ann Hematol. 2025 Sep 19. doi: 10.1007/s00277-025-06595.
   PubMed     Abstract available
   
   
   
3. REN Z, De Moerloose B, Lammens T
   Prime-time for LncRNA signatures in acute myeloid leukemia?
   Ann Hematol. 2025 Sep 18. doi: 10.1007/s00277-025-06616.
   PubMed     Abstract available
   
   
   
4. AZZA E, Ben Othmen A, Bahri M, Hsasna R, et al
   T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults.
   Ann Hematol. 2025 Sep 18. doi: 10.1007/s00277-025-06597.
   PubMed     Abstract available
   
   
   
5. LOPEZ-FERNANDEZ E, de Linares-Fernandez S, Perez-Marfil MN, Vera-Goni JA, et al
   Correction to: Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.
   Ann Hematol. 2025 Sep 5. doi: 10.1007/s00277-025-06603.
   PubMed    
   
   
   
6. WANG Y, Zong W, Fan J, Rong L, et al
   Rapidly progressing after umbilical cord blood transplantation in a boy with acute myeloid leukemia with KAT6A::EP300 fusion transcript.
   Ann Hematol. 2025 Sep 2. doi: 10.1007/s00277-025-06573.
   PubMed    
   
   
   August 2025
7. SANZ-SOLAS A, Saiz-Rodriguez M, Simal SC, Rodriguez-Veiga R, et al
   Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes.
   Ann Hematol. 2025 Aug 30. doi: 10.1007/s00277-025-06543.
   PubMed     Abstract available
   
   
   
8. LAZZAROTTO D, Testi AM, Fanin M, Mosna F, et al
   Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group.
   Ann Hematol. 2025 Aug 27. doi: 10.1007/s00277-025-06550.
   PubMed     Abstract available
   
   
   
9. RAJENDRA KURUP A, Malcolmson J, Villani A, Kim RH, et al
   Rare germline ETV6 variant associated with thrombocytopenia and acute leukemia.
   Ann Hematol. 2025 Aug 27. doi: 10.1007/s00277-025-06536.
   PubMed     Abstract available
   
   
   
10. YANG Y, Zhang X, Jiang N, Jin Y, et al
    Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2025 Aug 26. doi: 10.1007/s00277-025-06535.
    PubMed     Abstract available
    
    
    
11. GAO Q, Chen Y, Le S, Li N, et al
    Clinical characteristics and outcome of pediatric patients with high-risk acute promyelocytic leukemia, with special focus on risk factors of early death.
    Ann Hematol. 2025 Aug 12. doi: 10.1007/s00277-025-06528.
    PubMed     Abstract available
    
    
    
12. LI H, Gu Y, Zhao X, Ding G, et al
    Comparative longitudinal analysis of pulmonary function post-pediatric Allo-HSCT: benign vs. malignant diseases and early predictors.
    Ann Hematol. 2025;104:4201-4211.
    PubMed     Abstract available
    
    
    
13. HERLING M, Angelucci E, Benoit TM, Rivoli G, et al
    Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program.
    Ann Hematol. 2025;104:4121-4131.
    PubMed     Abstract available
    
    
    
14. WANG Y, Zhang Y, Liu J, Jiang Y, et al
    Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges.
    Ann Hematol. 2025;104:3929-3941.
    PubMed     Abstract available
    
    
    
15. BUCHRITS S, Trieman G, Giladi O, Hofstetter L, et al
    Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials.
    Ann Hematol. 2025;104:3903-3915.
    PubMed     Abstract available
    
    
    
16. ERNST J, Reinsch S, Mentzel HJ, Milde T, et al
    Successful treatment with mesenchymal stromal cells-Frankfurt am Main in a pediatric patient with steroid-refractory and ruxolitinib-refractory acute gastrointestinal graft-versus-host disease.
    Ann Hematol. 2025;104:4237-4243.
    PubMed     Abstract available
    
    
    
17. CIMINO G, Caridi M, Cardinali V, Sciabolacci S, et al
    Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports.
    Ann Hematol. 2025;104:4267-4271.
    PubMed     Abstract available
    
    
    July 2025
18. PARK H, Kim HJ, Sohn SK, Baik Y, et al
    Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor.
    Ann Hematol. 2025 Jul 31. doi: 10.1007/s00277-025-06514.
    PubMed     Abstract available
    
    
    
19. LAZAR DR, Maniu D, Lazar FL, Blag C, et al
    Exploring the baseline cardiac function and its correlation with risk stratification in children diagnosed with acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jul 30. doi: 10.1007/s00277-025-06523.
    PubMed     Abstract available
    
    
    
20. QUINQUENEL A, Lepretre S, Dilhuydy MS, Bussot L, et al
    Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).
    Ann Hematol. 2025 Jul 30. doi: 10.1007/s00277-025-06498.
    PubMed     Abstract available
    
    
    
21. HUANG L, Shi X, Tang N, Liu J, et al
    Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis.
    Ann Hematol. 2025 Jul 30. doi: 10.1007/s00277-025-06499.
    PubMed     Abstract available
    
    
    
22. BUONACQUISTO A, Del Principe MI, Pallotti F, Bianchini S, et al
    Semen quality in acute leukemia patients: a retrospective study.
    Ann Hematol. 2025 Jul 25. doi: 10.1007/s00277-025-06426.
    PubMed     Abstract available
    
    
    
23. LIU B, Yu T, Zhou N, Yi S, et al
    Biphenotypic NK-Large granular lymphocytic leukemia with aggressive clinical features: a case report and literature review.
    Ann Hematol. 2025 Jul 23. doi: 10.1007/s00277-025-06492.
    PubMed    
    
    
    
24. LOPEZ-FERNANDEZ E, de Linares-Fernandez S, Perez-Marfil MN, Rodriguez-Fernandez A, et al
    Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.
    Ann Hematol. 2025 Jul 22. doi: 10.1007/s00277-025-06516.
    PubMed     Abstract available
    
    
    
25. LIU D, Chen J, Luo Y, Yan S, et al
    Clinical features and fusion gene analysis of two Torque Teno Mini virus associated acute promyelocytic leukemia cases.
    Ann Hematol. 2025 Jul 18. doi: 10.1007/s00277-025-06501.
    PubMed     Abstract available
    
    
    
26. CHEN C, Huang Y, Wang L, Zhang L, et al
    Prognostic significance of angiogenesis-associated molecules and Immunologic characteristic in elderly patients with acute myeloid leukemia.
    Ann Hematol. 2025 Jul 17. doi: 10.1007/s00277-025-06454.
    PubMed     Abstract available
    
    
    
27. CHENG T, Peng J, Liu Y, Yang S, et al
    Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jul 11. doi: 10.1007/s00277-025-06471.
    PubMed     Abstract available
    
    
    
28. ZHANG D, Li Y, Liu T, Liu X, et al
    Efficacy and safety analysis of different treatment regimens in newly diagnosed acute promyelocytic leukemia.
    Ann Hematol. 2025 Jul 8. doi: 10.1007/s00277-025-06495.
    PubMed     Abstract available
    
    
    
29. ZIELINSKA P, Gruenpeter K, Wieczorkiewicz-Kabut A, Bialas K, et al
    Second allogeneic transplantation in relapsed acute leukemia - a risk worth taking?
    Ann Hematol. 2025 Jul 3. doi: 10.1007/s00277-025-06468.
    PubMed     Abstract available
    
    
    
30. IZUMI A, Tachibana T, Nukui J, Miyazaki T, et al
    Clinical significance of C-reactive protein/platelet ratio from diagnosis to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Ann Hematol. 2025 Jul 3. doi: 10.1007/s00277-025-06470.
    PubMed     Abstract available
    
    
    
31. CHEN X, Yuan L, Ma X, Wang F, et al
    TRAF3IP3::FGFR1: a novel FGFR1 fusion identified in an aggressive case of acute myeloid leukemia.
    Ann Hematol. 2025 Jul 1. doi: 10.1007/s00277-025-06494.
    PubMed    
    
    
    
32. KRETSCHMER L, Ruhnke L, Schliemann C, Fransecky L, et al
    VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.
    Ann Hematol. 2025;104:3647-3654.
    PubMed     Abstract available
    
    
    
33. RUBIO MA, Cisa-Wieczorek S, Mozos A, Castellet H, et al
    SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions.
    Ann Hematol. 2025;104:3655-3667.
    PubMed     Abstract available
    
    
    
34. MARAGLINO AME, Sammassimo S, Lolli G, Clemente A, et al
    Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.
    Ann Hematol. 2025;104:3875-3879.
    PubMed     Abstract available
    
    
    June 2025
35. CHEN X, Ren Y, Jin Y, Li X, et al
    First report of B-lymphoblastic leukemia harboring LRRFIP1::FGFR1 fusion: expanding the clinical spectrum of myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.
    Ann Hematol. 2025 Jun 30. doi: 10.1007/s00277-025-06481.
    PubMed    
    
    
    
36. GETZ TM, Bakirhan K, Seropian S, Shallis RM, et al
    Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review.
    Ann Hematol. 2025 Jun 27. doi: 10.1007/s00277-025-06388.
    PubMed     Abstract available
    
    
    
37. GIAMMARCO S, Chiusolo P, Metafuni E, Limongiello MA, et al
    Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center.
    Ann Hematol. 2025 Jun 23. doi: 10.1007/s00277-025-06462.
    PubMed    
    
    
    
38. LI X, Wang H, Han H, Qi J, et al
    Impact of ETV6 mutations on clinical outcomes in acute myeloid leukemia: a real-world retrospective cohort study.
    Ann Hematol. 2025 Jun 21. doi: 10.1007/s00277-025-06451.
    PubMed     Abstract available
    
    
    
39. CARDINALI V, Coiro S, Martelli MP, Sportoletti P, et al
    Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome.
    Ann Hematol. 2025 Jun 19. doi: 10.1007/s00277-025-06457.
    PubMed     Abstract available
    
    
    
40. CAO S, Cao C, Wang S
    Efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in aggressive NK-cell leukemia: a meta-analysis.
    Ann Hematol. 2025 Jun 5. doi: 10.1007/s00277-025-06423.
    PubMed     Abstract available
    
    
    
41. TANG J, Sun J, Liao J, Pu C, et al
    Down-regulation of circMUC16 inhibited the progression of ALL via interaction with miR-1182 and TPPP3.
    Ann Hematol. 2025;104:3389-3401.
    PubMed     Abstract available
    
    
    
42. NACHTKAMP K, Schulz F, Kasprzak A, Strupp C, et al
    Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS).
    Ann Hematol. 2025;104:3251-3259.
    PubMed     Abstract available
    
    
    
43. ZHOU EM, Tang Y, Liao C, Lin S, et al
    Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease.
    Ann Hematol. 2025;104:3495-3504.
    PubMed     Abstract available
    
    
    
44. WANG T, Zhao L, Ma H
    Impact of secondary-type mutations on the prognosis of AML patients with NPM1 mutation: a systematic review and meta-analysis.
    Ann Hematol. 2025;104:3103-3115.
    PubMed     Abstract available
    
    
    
45. CHEUNG CYM, Ha CY, Kho B, Lau CK, et al
    Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation.
    Ann Hematol. 2025;104:3091-3101.
    PubMed     Abstract available
    
    
    May 2025
46. SUN K, Shi ZY, Wang YZ, Xie DH, et al
    The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia.
    Ann Hematol. 2025 May 27. doi: 10.1007/s00277-025-06418.
    PubMed     Abstract available
    
    
    
47. TRAN QUANG V, Cretin J, Loyaux R, Ben Jedidia B, et al
    Subclonal emergence of polycythemia vera, chronic myelomonocytic leukemia, and chronic myeloid leukemia.
    Ann Hematol. 2025 May 24. doi: 10.1007/s00277-025-06417.
    PubMed     Abstract available
    
    
    
48. FIANCHI L, Piciocchi A, Guolo F, Marchesi F, et al
    Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study.
    Ann Hematol. 2025 May 24. doi: 10.1007/s00277-025-06381.
    PubMed     Abstract available
    
    
    
49. PARK S, Kim HK
    Epidemiologic sequential analysis of pure red blood cell aplasia and T-cell large granular lymphocyte leukemia in Korea.
    Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06406.
    PubMed     Abstract available
    
    
    
50. LIN J, Liu X, Ying S, Zhu Y, et al
    Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy.
    Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06399.
    PubMed     Abstract available
    
    
    
51. GRIMALDI F, Memoli M, Avilia S, Russo R, et al
    Molecular analysis of T-cell Acute Lymphoblastic Leukemia arising after Essential Thrombocythemia foreshadows a distinct clonal route for lymphoid blast crisis in Philadelphia-negative chronic myeloproliferative neoplasm: a case report with literary r
    Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06404.
    PubMed     Abstract available
    
    
    
52. ZHU T, Wang L, Jiang H, Huang S, et al
    Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study.
    Ann Hematol. 2025 May 20. doi: 10.1007/s00277-025-06389.
    PubMed     Abstract available
    
    
    
53. LEWANDOWSKI K, Janicki M, Baranska M, Kandula Z, et al
    Inotuzumab therapy resulted in molecular remission of relapsed/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation.
    Ann Hematol. 2025 May 16. doi: 10.1007/s00277-025-06385.
    PubMed     Abstract available
    
    
    
54. CECCHI N, Sciume M, Ricchiuti A, Bosi A, et al
    Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20.
    Ann Hematol. 2025 May 16. doi: 10.1007/s00277-025-06332.
    PubMed     Abstract available
    
    
    
55. SAMMARTANO V, Sicuranza A, Pacelli P, Bestoso E, et al
    Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia.
    Ann Hematol. 2025 May 15. doi: 10.1007/s00277-025-06401.
    PubMed     Abstract available
    
    
    
56. AVAL OS, Ahmadi A, Hemid Al-Athari AJ, Soleimani Samarkhazan H, et al
    "Galectin-9: A double-edged sword in Acute Myeloid Leukemia".
    Ann Hematol. 2025 May 9. doi: 10.1007/s00277-025-06387.
    PubMed     Abstract available
    
    
    
57. YOKOYAMA H, Fuji S, Murata M, Hirayama M, et al
    Impact of graft-versus-host disease on outcomes of cord blood transplantation according to HLA disparity and its prophylaxis type.
    Ann Hematol. 2025;104:2905-2913.
    PubMed     Abstract available
    
    
    
58. TURKINA A, Vinogradova O, Lomaia E, Shatokhina E, et al
    Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.
    Ann Hematol. 2025;104:2707-2715.
    PubMed     Abstract available
    
    
    
59. LIU J, Guo D, Lian H, Ding P, et al
    Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation.
    Ann Hematol. 2025;104:2915-2926.
    PubMed     Abstract available
    
    
    
60. MIAO L, Wang X, Yao M, Tao Y, et al
    Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis.
    Ann Hematol. 2025;104:2581-2591.
    PubMed     Abstract available
    
    
    
61. AN N, Bian K, Li C
    Alemtuzumab for haematological malignancies.
    Ann Hematol. 2025;104:2593-2603.
    PubMed     Abstract available
    
    
    
62. STUCKEY R, Navarrete Bullon L, Borrero Borrego A, Vidal Ballester V, et al
    Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs.
    Ann Hematol. 2025;104:3007-3009.
    PubMed     Abstract available
    
    
    
63. YANG X, Duan Y, Zhou C, Zhang N, et al
    A case series of B-Lymphoblastic lymphoma with C-MYC rearrangement in children: diagnostic and therapeutic challenges.
    Ann Hematol. 2025;104:3059-3066.
    PubMed     Abstract available
    
    
    
64. GARCIA M, Croizier C, Lazarian G, Quinquenel A, et al
    Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.
    Ann Hematol. 2025;104:2889-2895.
    PubMed     Abstract available
    
    
    April 2025
65. STOCK CN, Chillon CJ, Hernandez CL, Moro FM, et al
    Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemia.
    Ann Hematol. 2025 Apr 25. doi: 10.1007/s00277-025-06325.
    PubMed     Abstract available
    
    
    
66. MAHADEVIA H, Ponvilawan B, Shrestha A
    Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials.
    Ann Hematol. 2025 Apr 24. doi: 10.1007/s00277-025-06373.
    PubMed     Abstract available
    
    
    
67. LIU X, Chai X, Yu Q, Wang W, et al
    Clinical features and outcomes in large granular lymphocyte leukemia - associated pure red cell aplasia with STAT3 mutation.
    Ann Hematol. 2025 Apr 23. doi: 10.1007/s00277-025-06371.
    PubMed     Abstract available
    
    
    
68. WANG Y, Liu Q, Xu CL, Huang DP, et al
    Blinatumomab in combination with olverembatinib and concurrent intrathecal chemotherapy successfully treated a chronic myeloid leukemia relapse with central nervous system blast crisis: case report and literature review.
    Ann Hematol. 2025 Apr 9. doi: 10.1007/s00277-025-06351.
    PubMed     Abstract available
    
    
    
69. ZHOU Y, Zhang H, Zheng X, Zhang R, et al
    Impact of BCOR/BCORL1 mutation on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients.
    Ann Hematol. 2025 Apr 9. doi: 10.1007/s00277-025-06346.
    PubMed     Abstract available
    
    
    
70. PATRA PC, Rainchwar S, Singh R, Bhatia N, et al
    Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India.
    Ann Hematol. 2025;104:2483-2493.
    PubMed     Abstract available
    
    
    
71. FUJI S, Tokunaga M, Utsunomiya A, Makiyama J, et al
    Improving outcome prediction in indolent ATL by subdividing intermediate risk into low- and high-intermediate groups.
    Ann Hematol. 2025;104:2429-2436.
    PubMed     Abstract available
    
    
    March 2025
72. AN R, Bao W, Yan Z, Sun H, et al
    Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.
    Ann Hematol. 2025 Mar 31. doi: 10.1007/s00277-025-06310.
    PubMed     Abstract available
    
    
    
73. JAMIL A, Aslam S, Riaz R, Qureshi Z, et al
    Comparative efficacy of venetoclax-based regiments in the management of chronic lymphocytic leukemia: a systematic review and metanalysis.
    Ann Hematol. 2025 Mar 29. doi: 10.1007/s00277-025-06280.
    PubMed     Abstract available
    
    
    
74. YANG K, Yang B, Zhou Y, Huang Q, et al
    Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia.
    Ann Hematol. 2025 Mar 18. doi: 10.1007/s00277-025-06312.
    PubMed     Abstract available
    
    
    
75. MIRAZIMI Y, Aghayan AH, Atashi A, Mohammadi D, et al
    Prognostic value of circular RNAs expression and their correlation with clinicopathological features in acute myeloid leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2025 Mar 15. doi: 10.1007/s00277-025-06300.
    PubMed     Abstract available
    
    
    
76. ZHANG L, Lu Y, Jiang J, Wu G, et al
    Case report: single-cell transcriptome sequencing reveals the clonal origin of mature plasmacytoid dendritic cell proliferation in early T-cell precursor lymphoblastic leukemia.
    Ann Hematol. 2025 Mar 14. doi: 10.1007/s00277-025-06301.
    PubMed     Abstract available
    
    
    
77. JIANG B, Li J, Liu L, Du X, et al
    Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia.
    Ann Hematol. 2025 Mar 10. doi: 10.1007/s00277-025-06235.
    PubMed     Abstract available
    
    
    
78. GUTIERREZ DE MORAES PEREIRA GB, Rocha VA, Barbosa PVR, Cralcev C, et al
    Twin pregnancy during treatment with asciminib for chronic myeloid leukemia - a case report.
    Ann Hematol. 2025 Mar 8. doi: 10.1007/s00277-025-06238.
    PubMed     Abstract available
    
    
    
79. SONG BQ, Kong X, Liu Y, Pu Y, et al
    Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML.
    Ann Hematol. 2025;104:1617-1622.
    PubMed     Abstract available
    
    
    
80. NIYONIZEYE E, Wang X, Yan D, Richard SA, et al
    Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping.
    Ann Hematol. 2025;104:1807-1819.
    PubMed     Abstract available
    
    
    
81. PAN H, Gao Z, Lian Y, Zhao J, et al
    Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study.
    Ann Hematol. 2025;104:1597-1604.
    PubMed     Abstract available
    
    
    
82. MENG M, Feng X, Zhang Y, Gao Y, et al
    Efficacy and mechanism of the XPO1 inhibitor selinexor combined with decitabine in T-cell lymphoblastic lymphoma.
    Ann Hematol. 2025;104:1747-1756.
    PubMed     Abstract available
    
    
    
83. MOUSAVI S, Nouri S, Sadeghipour A, Atashi A, et al
    Tumor microenvironment as a novel therapeutic target for lymphoid leukemias.
    Ann Hematol. 2025;104:1367-1386.
    PubMed     Abstract available
    
    
    
84. LEE BJ
    Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm.
    Ann Hematol. 2025;104:2069-2071.
    PubMed     Abstract available
    
    
    
85. HUANG G, Cai X, Li D
    Significance of targeting DNMT3A mutations in AML.
    Ann Hematol. 2025;104:1399-1414.
    PubMed     Abstract available
    
    
    February 2025
86. HORNAK T, Zackova D, Mayer J
    Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib.
    Ann Hematol. 2025 Feb 28. doi: 10.1007/s00277-025-06228.
    PubMed     Abstract available
    
    
    
87. FANG Y, Zhao M, Luo T, Cui J, et al
    Prediction of survival in acute myeloid leukemia patients by extracellular to intracellular water ratio and sarcopenia: development and validation of a novel nomogram.
    Ann Hematol. 2025 Feb 18. doi: 10.1007/s00277-025-06248.
    PubMed     Abstract available
    
    
    
88. HAO L, Yao Y, Yang L
    Thromboembolism in adult patients with acute promyelocytic leukemia: clinical characteristics, risk factors, and a predictive nomogram.
    Ann Hematol. 2025 Feb 18. doi: 10.1007/s00277-025-06251.
    PubMed     Abstract available
    
    
    
89. IBERTI M, Loschi M, Keslair F, Deckert M, et al
    Novel ETV6::RAPGEF6 fusion gene in chronic eosinophilic leukemia: compiling evidence on the role of IL3 overexpression in tumorigenesis.
    Ann Hematol. 2025 Feb 9. doi: 10.1007/s00277-025-06217.
    PubMed     Abstract available
    
    
    
90. IYAMA S, Chi S, Idogawa M, Ikezoe T, et al
    Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study.
    Ann Hematol. 2025 Feb 8. doi: 10.1007/s00277-025-06227.
    PubMed     Abstract available
    
    
    
91. SHUMILOV E, Mazzeo P, Trautmann M, Levien L, et al
    Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia.
    Ann Hematol. 2025 Feb 6. doi: 10.1007/s00277-025-06230.
    PubMed     Abstract available
    
    
    
92. SHAFIEIZADEGAN S, Aberuyi N, Rahgozar S
    The molecular impact of miR-326 in acute lymphoblastic leukemia and its cross talk with P53.
    Ann Hematol. 2025 Feb 5. doi: 10.1007/s00277-024-06181.
    PubMed     Abstract available
    
    
    
93. CULLOT G, Lagarde V, Cayuela JM, Prouzet-Mauleon V, et al
    Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.
    Ann Hematol. 2025;104:1117-1126.
    PubMed     Abstract available
    
    
    
94. LIN L, Yang KH, Chen CC, Shen SH, et al
    Risk factors and a prediction model of severe asparaginase-associated pancreatitis in children.
    Ann Hematol. 2025;104:1015-1022.
    PubMed     Abstract available
    
    
    
95. SOLANA-ALTABELLA A, Rodriguez-Veiga R, Martinez-Cuadron D, Montesinos P, et al
    A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?
    Ann Hematol. 2025;104:913-935.
    PubMed     Abstract available
    
    
    January 2025
96. YIGIT KAYA S, Vatani M, Akil R, Cakir T, et al
    A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.
    Ann Hematol. 2025 Jan 23. doi: 10.1007/s00277-024-06118.
    PubMed     Abstract available
    
    
    
97. ZHENG J, Zhou Y, Zhao Y, Luo Y, et al
    Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogene
    Ann Hematol. 2025 Jan 23. doi: 10.1007/s00277-025-06202.
    PubMed     Abstract available
    
    
    
98. HIDALGO-GOMEZ G, Tazon-Vega B, Palacio C, Saumell S, et al
    How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jan 23. doi: 10.1007/s00277-024-06151.
    PubMed     Abstract available
    
    
    
99. MASUDA Y, Sadato D, Toya T, Hirama C, et al
    Telomere shortening in donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation: a case report.
    Ann Hematol. 2025 Jan 22. doi: 10.1007/s00277-025-06222.
    PubMed     Abstract available
    
    
    
100. YE Y, Zhao Z, Mo W, Liu W, et al
     Zebrafish modeling of atypical PML-RARA isoform from acute promyelocytic leukemia patient and its implications for clinical treatment.
     Ann Hematol. 2025 Jan 21. doi: 10.1007/s00277-024-06169.
     PubMed     Abstract available
     
     
     
101. SOSSA-MELO C, Abello-Polo V, Salazar LA, Pena AM, et al
     Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study.
     Ann Hematol. 2025 Jan 16. doi: 10.1007/s00277-024-06120.
     PubMed     Abstract available
     
     
     
102. KONG J, Zheng FM, Yan CH, Wang JZ, et al
     Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
     Ann Hematol. 2025 Jan 16. doi: 10.1007/s00277-025-06198.
     PubMed     Abstract available
     
     
     
103. SCHULZ F, Roggenbuck C, Kundgen A, Kasprzak A, et al
     Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.
     Ann Hematol. 2025 Jan 11. doi: 10.1007/s00277-025-06196.
     PubMed     Abstract available
     
     
     
104. SHAKEEL L, Khaliq N, Shaukat A, Khan A, et al
     The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
     Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06121.
     PubMed     Abstract available
     
     
     
105. YOUSEFI A, Levin MD, Cornelissen JJ, Westerweel PE, et al
     Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases.
     Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06170.
     PubMed     Abstract available
     
     
     
106. JIMBO K, Ishigaki T, Sakashita M, Andoh S, et al
     Prognosis of aggressive adult T-cell leukemia/lymphoma with central nervous system infiltration and utility of CD7 versus CADM1 flowcytometric plots of cerebrospinal fluid.
     Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-025-06186.
     PubMed     Abstract available
     
     
     
107. YU S, Yang S, Hu L, Duan W, et al
     Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia.
     Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06182.
     PubMed     Abstract available
     
     
     
108. JIN S, Chang M, Feng L, Hao Y, et al
     PEG-rhG-CSF versus rhG-CSF in supporting neutrophil recovery after induction chemotherapy for patients with newly diagnosed acute lymphoblastic leukemia.
     Ann Hematol. 2025 Jan 8. doi: 10.1007/s00277-025-06183.
     PubMed     Abstract available
     
     
     
109. BUZZATTI E, Botti C, Presicci R, Mauro C, et al
     A fatal case of peritonitis due to colonic localization of acute myeloid leukemia.
     Ann Hematol. 2025 Jan 7. doi: 10.1007/s00277-024-06172.
     PubMed     Abstract available
     
     
     
110. OH YE, Min GJ, Jeon YW, Kim TY, et al
     Long-term clinical outcome of a weekly 2-chlorodeoxyadenosine regimen in treatment-naive patients with hairy cell leukemia.
     Ann Hematol. 2025 Jan 4. doi: 10.1007/s00277-024-06173.
     PubMed     Abstract available
     
     
     
111. MAFFEI R, Paolini A, Conte B, Riva G, et al
     Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia.
     Ann Hematol. 2025;104:263-274.
     PubMed     Abstract available
     
     
     
112. HUANG N, Song Y, Wu L, He Q, et al
     Validation and improvement of the molecular international prognostic scoring system in Chinese patients with myelodysplastic syndromes.
     Ann Hematol. 2025;104:193-206.
     PubMed     Abstract available
     
     
     
113. HOSOBA R, Fukuhara S, Kogure Y, Takano K, et al
     Whole exome sequencing analysis of a patient with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions with ETV6::LYN fusion gene.
     Ann Hematol. 2025;104:809-813.
     PubMed     Abstract available
     
     
     
114. HULS G, Chitu DA, Tick L, Boersma R, et al
     Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
     Ann Hematol. 2025;104:361-368.
     PubMed     Abstract available
     
     
     
115. GIELIS S, Flumens D, van der Heijden S, Versteven M, et al
     Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed.
     Ann Hematol. 2025;104:317-333.
     PubMed     Abstract available
     
     
     December 2024
116. LIU Q, Zhao J, Li Y, Jia Y, et al
     Comparative safety of different first-line treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic review and network meta-analysis.
     Ann Hematol. 2024 Dec 28. doi: 10.1007/s00277-024-06136.
     PubMed     Abstract available
     
     
     
117. ZHAO Y, Yu X, Yan L, Shi D, et al
     Study on clinical features of early death in older patients with acute promyelocytic leukemia.
     Ann Hematol. 2024 Dec 27. doi: 10.1007/s00277-024-06165.
     PubMed     Abstract available
     
     
     
118. SUGIHARA A, Kubota Y, Nagaie T, Fujita M, et al
     Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report.
     Ann Hematol. 2024 Dec 21. doi: 10.1007/s00277-024-06153.
     PubMed     Abstract available
     
     
     
119. MA JF, Yan CL, Jia X, Zhu HJ, et al
     Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.
     Ann Hematol. 2024 Dec 18. doi: 10.1007/s00277-024-06132.
     PubMed     Abstract available
     
     
     
120. TANG X, Liu S, Hu Y, Chen F, et al
     Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry.
     Ann Hematol. 2024 Dec 13. doi: 10.1007/s00277-024-06126.
     PubMed     Abstract available
     
     
     
121. LI W, Ma R, Fan X, Xiao Z, et al
     M1 macrophage-derived exosomes alleviate leukemia by causing mitochondrial dysfunction.
     Ann Hematol. 2024 Dec 12. doi: 10.1007/s00277-024-06138.
     PubMed     Abstract available
     
     
     
122. SANCHEZ-MENDOZA SE, de Deus-Wagatsuma VM, do Nascimento MC, Lima K, et al
     All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations.
     Ann Hematol. 2024 Dec 11. doi: 10.1007/s00277-024-06089.
     PubMed     Abstract available
     
     
     
123. CHANSWANGPHUWANA C, Sukswai N, Tangnuntachai N, Rojnuckarin P, et al
     Survival impact of hypoxia-inducible factor-1 alpha (HIF-1alpha) in Nucleophosmin1 mutated acute myeloid leukemia.
     Ann Hematol. 2024 Dec 4. doi: 10.1007/s00277-024-06124.
     PubMed     Abstract available
     
     
     
124. MATSUKAWA T, Onozawa M, Kondo T, Kanaya M, et al
     FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML.
     Ann Hematol. 2024;103:5333-5340.
     PubMed     Abstract available
     
     
     
125. TAUVERON-JALENQUES U, Sarr K, Guieze R, Giordano C, et al
     Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia.
     Ann Hematol. 2024;103:5985-5988.
     PubMed     Abstract available
     
     
     
126. BIN T, Tang J, Lu B, Xu XJ, et al
     Construction of AML prognostic model with CYP2E1 and GALNT12 biomarkers based on golgi- associated genes.
     Ann Hematol. 2024;103:5297-5314.
     PubMed     Abstract available
     
     
     
127. KOUIDRI K, Acker F, Toenges R, Pfaff S, et al
     Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.
     Ann Hematol. 2024;103:5387-5393.
     PubMed     Abstract available
     
     
     
128. CUI K, Zhang S, Wang Q, Wei Y, et al
     Prognostic significance of early nk cell recovery in pediatric t-cell replete allogeneic hematopoietic stem cell transplantation.
     Ann Hematol. 2024;103:5769-5780.
     PubMed     Abstract available
     
     
     
129. PUZO CJ, Hager KM, Rinder HM, Weinberg OK, et al
     Overall survival in TP53-mutated AML and MDS.
     Ann Hematol. 2024;103:5359-5369.
     PubMed     Abstract available
     
     
     
130. LEE BJ, Griffin SP, Doh J, Ciurea SO, et al
     Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.
     Ann Hematol. 2024;103:5395-5403.
     PubMed     Abstract available
     
     
     
131. SUN Y, Wang Q, Zhang Z, Wang Q, et al
     Distinct clinical profiles and patient outcomes in aCML and CNL.
     Ann Hematol. 2024;103:5325-5332.
     PubMed     Abstract available
     
     
     
132. HAN X, Liu W, Kang Z, Li D, et al
     Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis.
     Ann Hematol. 2024;103:4943-4952.
     PubMed     Abstract available
     
     
     
133. JAFARI PA, Bagheri R, Lavasani S, Goudarzi S, et al
     DNMT3A-R882: a mutation with many paradoxes.
     Ann Hematol. 2024;103:4981-4988.
     PubMed     Abstract available
     
     
     November 2024
134. BERNARDI S, Cavalleri A, Mutti S, Garuffo L, et al
     Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.
     Ann Hematol. 2024 Nov 29. doi: 10.1007/s00277-024-06100.
     PubMed     Abstract available
     
     
     
135. LI J, Chen J, Wang Q, Ou J, et al
     Clonal evolution defines risk stratification for central nervous system leukemia in adult acute lymphoblastic leukemia.
     Ann Hematol. 2024 Nov 29. doi: 10.1007/s00277-024-06116.
     PubMed     Abstract available
     
     
     
136. ZHA C, Yang X, Yang J, Zhang Y, et al
     Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies.
     Ann Hematol. 2024 Nov 28. doi: 10.1007/s00277-024-06117.
     PubMed     Abstract available
     
     
     
137. LI Y, Zhang Q, Shao H
     Recurrent PAX5::ZCCHC7 rearrangement in B-cell acute lymphoblastic leukemia.
     Ann Hematol. 2024 Nov 27. doi: 10.1007/s00277-024-06114.
     PubMed     Abstract available
     
     
     
138. ABDELFATTAH NE, Elsayed GM, Soliman AH, Ebeid EN, et al
     Copy number alterations in pediatric B-cell precursor acute lymphoblastic leukemia patients and their association with patients' outcome.
     Ann Hematol. 2024 Nov 26. doi: 10.1007/s00277-024-06102.
     PubMed     Abstract available
     
     
     
139. MA H, Du Y, Li J, Rao J, et al
     Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study.
     Ann Hematol. 2024 Nov 26. doi: 10.1007/s00277-024-06097.
     PubMed     Abstract available
     
     
     
140. HE Y, Ding J, Liu L, Chen J, et al
     Investigation of TSRP reverses imatinib resistance through the PI3K / Akt pathway in chronic myeloid leukemia.
     Ann Hematol. 2024 Nov 25. doi: 10.1007/s00277-024-06099.
     PubMed     Abstract available
     
     
     
141. CHEN X, Ma X, Yuan L, Wang F, et al
     The second adult case of NUTM1 fusion-positive B-cell lymphoblastic leukemia: A recurring pattern of poor prognosis.
     Ann Hematol. 2024 Nov 25. doi: 10.1007/s00277-024-06115.
     PubMed     Abstract available
     
     
     
142. FLEISCHMANN M, Jentzsch M, Brioli A, Eisele F, et al
     Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
     Ann Hematol. 2024 Nov 20. doi: 10.1007/s00277-024-06095.
     PubMed    
     
     
     
143. BLANKSTEIN AR, Choi N, Mozessohn L, Sanford D, et al
     Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists.
     Ann Hematol. 2024 Nov 20. doi: 10.1007/s00277-024-06085.
     PubMed     Abstract available
     
     
     
144. MIZUNO S, Hosoi H, Takami A, Kawata T, et al
     Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
     Ann Hematol. 2024 Nov 19. doi: 10.1007/s00277-024-06094.
     PubMed     Abstract available
     
     
     
145. AU WY, Chow C, To KF, Ma ESK, et al
     Mixed-phenotype leukemia with TCF3::ZNF384 fusion presenting as an isolated mediastinal mass.
     Ann Hematol. 2024 Nov 12. doi: 10.1007/s00277-024-06042.
     PubMed     Abstract available
     
     
     
146. TOLOZA MJ, Lincango M, Camacho MF, Ledesma MM, et al
     Immune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia.
     Ann Hematol. 2024 Nov 7. doi: 10.1007/s00277-024-06074.
     PubMed     Abstract available
     
     
     
147. MONSEREENUSORN C, Techavichit P, Sathitsamitphong L, Lertvivatpong N, et al
     Enhancing outcomes of childhood acute lymphoblastic leukemia in workplace diversity in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
     Ann Hematol. 2024 Nov 5. doi: 10.1007/s00277-024-06068.
     PubMed     Abstract available
     
     
     
148. HUANG N, Chang C, Wu L, He Q, et al
     Distinct mutation features and its clinical significance in myelodysplastic syndromes with normal karyotype.
     Ann Hematol. 2024;103:4485-4495.
     PubMed     Abstract available
     
     
     
149. SPATH C, Neumann T, Kruger WH
     Antileukaemic rescue by dose-dense donor-lymphocyte infusions in T-PLL after allogeneic stem cell transplantation - a case report.
     Ann Hematol. 2024;103:4777-4778.
     PubMed     Abstract available
     
     
     October 2024
150. ZHENG S, Tong Y, Yang L, Chen J, et al
     The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.
     Ann Hematol. 2024 Oct 29. doi: 10.1007/s00277-024-06050.
     PubMed     Abstract available
     
     
     
151. FORGHIERI F, Bettelli F, Sgromo S, Nadali G, et al
     Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group.
     Ann Hematol. 2024 Oct 28. doi: 10.1007/s00277-024-06047.
     PubMed    
     
     
     
152. MCCLELLAN K, Messina J, Saullo J, Huggins J, et al
     Incidence of infection in patients with acute myeloid leukemia receiving high-dose cytarabine consolidation.
     Ann Hematol. 2024 Oct 27. doi: 10.1007/s00277-024-06069.
     PubMed     Abstract available
     
     
     
153. FLEISCHMANN M, Jentzsch M, Brioli A, Eisele F, et al
     Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
     Ann Hematol. 2024 Oct 25. doi: 10.1007/s00277-024-06048.
     PubMed     Abstract available
     
     
     
154. EFFICACE F, Sparano F, Breccia M, Greco C, et al
     Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial.
     Ann Hematol. 2024 Oct 23. doi: 10.1007/s00277-024-06038.
     PubMed     Abstract available
     
     
     
155. LI S, Gao R, Han X, Wang K, et al
     MALAT1/miR-582-5p/GALNT1/MUC1 axis modulates progression of AML leukemia stem cells by regulating JAK2/STAT3 pathway.
     Ann Hematol. 2024 Oct 21. doi: 10.1007/s00277-024-06043.
     PubMed     Abstract available
     
     
     
156. TRIPATHI S, K V VB, Nayak AR, Chauhan R, et al
     Ischemic stroke as a presenting feature of promyelocytic blast phase in chronic myeloid leukemia - an uncommon presentation: a case report and literature review in the post imatinib era.
     Ann Hematol. 2024 Oct 16. doi: 10.1007/s00277-024-06044.
     PubMed     Abstract available
     
     
     
157. SCALZULLI E, Costa A, Carmosino I, Musiu P, et al
     Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time.
     Ann Hematol. 2024 Oct 15. doi: 10.1007/s00277-024-06014.
     PubMed     Abstract available
     
     
     
158. ZHU Y, Huang J, Wang Y, Han Y, et al
     Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
     Ann Hematol. 2024 Oct 14. doi: 10.1007/s00277-024-06027.
     PubMed     Abstract available
     
     
     
159. YANG L, Ma D, Liu S, Zou L, et al
     The DHODH inhibitor teriflunomide impedes cell proliferation and enhances chemosensitivity to daunorubicin (DNR) in T-cell acute lymphoblastic leukemia.
     Ann Hematol. 2024 Oct 8. doi: 10.1007/s00277-024-05998.
     PubMed     Abstract available
     
     
     
160. WERY AR, Salaroli A, Andreozzi F, Paesmans M, et al
     Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study.
     Ann Hematol. 2024 Oct 4. doi: 10.1007/s00277-024-06017.
     PubMed     Abstract available
     
     
     
161. LI HD, Chen SS, Ding J, Zhang CL, et al
     Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations.
     Ann Hematol. 2024;103:4295-4304.
     PubMed     Abstract available
     
     
     
162. CHEN CY
     Chromothripsis in myeloid malignancies.
     Ann Hematol. 2024;103:3955-3962.
     PubMed     Abstract available
     
     
     
163. GAO Y, Xi Y, Chen W, Meng Y, et al
     Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide.
     Ann Hematol. 2024;103:3947-3954.
     PubMed     Abstract available
     
     
     
164. GE S, Wang J, He Q, Zhu J, et al
     Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML.
     Ann Hematol. 2024;103:3855-3866.
     PubMed     Abstract available
     
     
     September 2024
165. PAN YS, Li H, Yang M, Zhang CL, et al
     A case of visual impairment due to HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation in childhood acute myeloid leukemia-M2 subtype.
     Ann Hematol. 2024 Sep 30. doi: 10.1007/s00277-024-06030.
     PubMed     Abstract available
     
     
     
166. AHMAD F, Shah A, Angi M, Narmawala Q, et al
     Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report.
     Ann Hematol. 2024 Sep 27. doi: 10.1007/s00277-024-05966.
     PubMed     Abstract available
     
     
     
167. HAGIHARA M, Yasu T, Gando Y, Sugi T, et al
     Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia.
     Ann Hematol. 2024 Sep 27. doi: 10.1007/s00277-024-05845.
     PubMed     Abstract available
     
     
     
168. KRAMP LJ, Heydrich-Karsten C, Sembill S, Karow A, et al
     CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase.
     Ann Hematol. 2024 Sep 21. doi: 10.1007/s00277-024-06011.
     PubMed     Abstract available
     
     
     
169. DUAN W, Jia J, Wang J, Liu X, et al
     Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival.
     Ann Hematol. 2024 Sep 17. doi: 10.1007/s00277-024-06001.
     PubMed     Abstract available
     
     
     
170. ZHAO Z, Lan J
     Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia.
     Ann Hematol. 2024 Sep 16. doi: 10.1007/s00277-024-06008.
     PubMed     Abstract available
     
     
     
171. YANG S, Huang H, Zhou K, Zhao X, et al
     Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial.
     Ann Hematol. 2024 Sep 14. doi: 10.1007/s00277-024-05978.
     PubMed     Abstract available
     
     
     
172. PEREZ-LAMAS L, Diaz AS, Castera EM, Soto MH, et al
     Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.
     Ann Hematol. 2024 Sep 13. doi: 10.1007/s00277-024-05906.
     PubMed     Abstract available
     
     
     
173. ATNAF A, Akelew Y, Abebaw D, Muche Y, et al
     The role of long noncoding RNAs in the diagnosis, prognosis and therapeutic biomarkers of acute myeloid leukemia.
     Ann Hematol. 2024 Sep 12. doi: 10.1007/s00277-024-05987.
     PubMed     Abstract available
     
     
     
174. HAN P, Wei S, Wang H, Cai Y, et al
     Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade.
     Ann Hematol. 2024 Sep 12. doi: 10.1007/s00277-024-06003.
     PubMed     Abstract available
     
     
     
175. SIFFEL C, Richter J, Anderson-Smits C, Kamieniak M, et al
     Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study.
     Ann Hematol. 2024 Sep 12. doi: 10.1007/s00277-024-05984.
     PubMed     Abstract available
     
     
     
176. JAIN AG, Volpe VO, Wang C, Ball S, et al
     Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia.
     Ann Hematol. 2024 Sep 7. doi: 10.1007/s00277-024-05976.
     PubMed     Abstract available
     
     
     
177. WEI Y, Qian K, Le N, Wang L, et al
     Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.
     Ann Hematol. 2024 Sep 7. doi: 10.1007/s00277-024-05972.
     PubMed     Abstract available
     
     
     
178. STEINER N, Baier K, Ritter D, Rudzki J, et al
     Early autologous and/or allogeneic stem cell transplantation for adult patients with advanced stage T- lymphoblastic leukemia/lymphoma or Burkitt lymphoma. A retrospective single-centre analysis.
     Ann Hematol. 2024 Sep 3. doi: 10.1007/s00277-024-05979.
     PubMed     Abstract available
     
     
     
179. TALEBI E, Ghoraeian P, Shams Z, Rahimi H, et al
     Molecular insights into the hedgehog signaling pathway correlated non-coding RNAs in acute lymphoblastic leukemia, a bioinformatics study.
     Ann Hematol. 2024 Sep 3. doi: 10.1007/s00277-024-05763.
     PubMed     Abstract available
     
     
     
180. SOBAS M, Ianotto JC, Kiladjian JJ, Harrison C, et al
     Myeloproliferative neoplasms: young patients, current data and future considerations.
     Ann Hematol. 2024;103:3287-3291.
     PubMed     Abstract available
     
     
     
181. GUARNERA L, Tiravanti I, Guiducci A, Coppola L, et al
     Prophylaxis with Tixagevimab/Cilgavimab in chronic lymphocytic leukaemia, a case control study.
     Ann Hematol. 2024;103:3831-3833.
     PubMed    
     
     
     
182. HUA W, Qi J, Zhou M, Han S, et al
     Overexpression of REC8 induces aberrant gamete meiotic division and contributes to AML pathogenesis - a multiplexed microarray analysis and mendelian randomization study.
     Ann Hematol. 2024;103:3563-3572.
     PubMed     Abstract available
     
     
     
183. COX ER, Summers C, Milano F, Dahlberg A, et al
     Outcomes of patients undergoing third hematopoietic cell transplantation for hematologic malignancies.
     Ann Hematol. 2024;103:3737-3743.
     PubMed     Abstract available
     
     
     
184. CHEN F
     ETV6::ABL1 positive myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) with blast crisis treated with flumatinib mesylate.
     Ann Hematol. 2024;103:3801-3804.
     PubMed     Abstract available
     
     
     
185. ROZENTAL A, Halperin E, Leibovitch C, Barzili M, et al
     CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study.
     Ann Hematol. 2024;103:3585-3594.
     PubMed     Abstract available
     
     
     
186. HU L, Li Z, Yang S, Zhao T, et al
     Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome-positive acute lymphoblastic leukaemia.
     Ann Hematol. 2024;103:3745-3754.
     PubMed     Abstract available
     
     
     
187. YANG M, Tang Y, Zhu P, Lu H, et al
     The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia.
     Ann Hematol. 2024;103:3385-3398.
     PubMed     Abstract available
     
     
     
188. WEI Z, Su L, Gao S
     The roles of ubiquitination in AML.
     Ann Hematol. 2024;103:3413-3428.
     PubMed     Abstract available
     
     
     August 2024
189. XU Q, Li H, Huang P, Lin W, et al
     Investigation of infections status in pediatric patients with acute myeloid leukemia during the induction period-a retrospective study in two medical centers.
     Ann Hematol. 2024 Aug 31. doi: 10.1007/s00277-024-05939.
     PubMed     Abstract available
     
     
     
190. JIMENEZ-VICENTE C, Guardia-Torrelles A, Perez-Valencia AI, Martinez-Roca A, et al
     Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study.
     Ann Hematol. 2024 Aug 29. doi: 10.1007/s00277-024-05923.
     PubMed     Abstract available
     
     
     
191. KLOS C, Roynard P, Berthon C, Soenen V, et al
     Unravelling a KMT2A::ARHGEF12 fusion within chromoanagenesis in acute myeloid leukemia using Optical Genome Mapping.
     Ann Hematol. 2024 Aug 29. doi: 10.1007/s00277-024-05948.
     PubMed    
     
     
     
192. PRAJAPATI SK, Kumari N, Bhowmik D, Gupta R, et al
     Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia.
     Ann Hematol. 2024 Aug 29. doi: 10.1007/s00277-024-05963.
     PubMed     Abstract available
     
     
     
193. SOLIS-ARMENTA R, Rodriguez-Rodriguez S, Hernandez-Perez AP, Paulina-Zapata N, et al
     Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis.
     Ann Hematol. 2024 Aug 23. doi: 10.1007/s00277-024-05956.
     PubMed     Abstract available
     
     
     
194. BADER MS, Kubetzko S, Schafer BW, Arranto C, et al
     Minimal residual disease monitoring by Ig/TCR gene rearrangements predicts post-transplant relapse and survival in adult patients with acute lymphoblastic leukemia.
     Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05943.
     PubMed    
     
     
     
195. MENG Z, Zheng H, Liu Y, Guo X, et al
     Prognostic significance of CRLF2 in patients with acute lymphoblastic leukemia: a meta-analysis and systematic review.
     Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05667.
     PubMed     Abstract available
     
     
     
196. YANG Y, Wang L, Peng Y, Nie X, et al
     Analysis of the occurrence and liver function characteristics of arsenic-associated liver injury during the treatment of pediatric patients with acute promyelocytic leukemia.
     Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05954.
     PubMed     Abstract available
     
     
     
197. SUGITA J, Morita K, Konuma T, Yanada M, et al
     Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.
     Ann Hematol. 2024 Aug 17. doi: 10.1007/s00277-024-05944.
     PubMed     Abstract available
     
     
     
198. NUNES RAB, Avezum A, de Oliveira Marques M, Baiocchi OCCG, et al
     Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
     Ann Hematol. 2024 Aug 17. doi: 10.1007/s00277-024-05921.
     PubMed     Abstract available
     
     
     
199. TARANTINI F, Cumbo C, Parciante E, Anelli L, et al
     IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative neoplasms.
     Ann Hematol. 2024 Aug 15. doi: 10.1007/s00277-024-05938.
     PubMed    
     
     
     
200. YAO Y, Zhou J, Li Y, Shi S, et al
     CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia.
     Ann Hematol. 2024 Aug 15. doi: 10.1007/s00277-024-05945.
     PubMed    
     
     
     
201. SU Z, Cong B, Dong P
     A novel FNDC3B::MECOM fusion gene accompanied with Der(5; 17)(p10; q10) in acute myelocytic leukemia.
     Ann Hematol. 2024 Aug 14. doi: 10.1007/s00277-024-05930.
     PubMed    
     
     
     
202. LAU C, van Kesteren C, Cao YX, Smeenk RM, et al
     Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series.
     Ann Hematol. 2024 Aug 12. doi: 10.1007/s00277-024-05924.
     PubMed     Abstract available
     
     
     
203. FORGHIERI F, Cordella S, Marchesi F, Itri F, et al
     Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemi
     Ann Hematol. 2024 Aug 8. doi: 10.1007/s00277-024-05927.
     PubMed    
     
     
     
204. WANG SX, Wang F, Tu YC, Zhou YL, et al
     Rare case of simultaneous occurrence of chronic neutrophil leukemia and T lymphoblastic lymphoma: case report and literature review.
     Ann Hematol. 2024 Aug 6. doi: 10.1007/s00277-024-05759.
     PubMed     Abstract available
     
     
     
205. TAMELLINI E, Simio C, Bernardelli A, Ferrarini I, et al
     Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report.
     Ann Hematol. 2024 Aug 3. doi: 10.1007/s00277-024-05922.
     PubMed     Abstract available
     
     
     
206. GUO W, Zhang H, Wang M, Zheng Y, et al
     WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients.
     Ann Hematol. 2024;103:2827-2836.
     PubMed     Abstract available
     
     
     
207. CHOQUET S, Marchal C, Deygas F, Deslandes M, et al
     A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS).
     Ann Hematol. 2024;103:2969-2981.
     PubMed     Abstract available
     
     
     
208. GUO W, Zhang H, Zheng Y, Gao H, et al
     Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT.
     Ann Hematol. 2024;103:3155-3163.
     PubMed     Abstract available
     
     
     
209. SUAREZ EU, Boluda B, Lavilla E, Tormo M, et al
     Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
     Ann Hematol. 2024;103:2845-2851.
     PubMed     Abstract available
     
     
     
210. SHI H, Yang F, Cao M, Xu T, et al
     Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.
     Ann Hematol. 2024;103:2993-3004.
     PubMed     Abstract available
     
     
     
211. KT MF, Semwal M, Yoosuf BT, Lad D, et al
     Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS.
     Ann Hematol. 2024;103:3179-3191.
     PubMed     Abstract available
     
     
     
212. HU R, Liao P, Xu B, Qiu Y, et al
     N6-methyladenosine RNA modifications: a potential therapeutic target for AML.
     Ann Hematol. 2024;103:2601-2612.
     PubMed     Abstract available
     
     
     July 2024
213. DENG J, Qin X, Ma G, Shen X, et al
     Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.
     Ann Hematol. 2024 Jul 29. doi: 10.1007/s00277-024-05862.
     PubMed     Abstract available
     
     
     
214. FAN BE, Chow M
     Artificial intelligence assisted diagnosis of chronic lymphocytic leukemia in a historic pediatric case using large language models.
     Ann Hematol. 2024 Jul 29. doi: 10.1007/s00277-024-05916.
     PubMed    
     
     
     
215. ROBAK T, Pula A, Braun M, Robak E, et al
     Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.
     Ann Hematol. 2024 Jul 25. doi: 10.1007/s00277-024-05854.
     PubMed     Abstract available
     
     
     
216. DAI Y, Luo L, Wei Z, Cheng P, et al
     The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience.
     Ann Hematol. 2024 Jul 24. doi: 10.1007/s00277-024-05892.
     PubMed     Abstract available
     
     
     
217. LIPTON JH, Brummendorf TH, Sweet K, Apperley JF, et al
     Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia.
     Ann Hematol. 2024 Jul 18. doi: 10.1007/s00277-024-05851.
     PubMed     Abstract available
     
     
     
218. ZHAO Y, Huang Y, Jiang L, Zhang Y, et al
     Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.
     Ann Hematol. 2024 Jul 18. doi: 10.1007/s00277-024-05884.
     PubMed     Abstract available
     
     
     
219. KONTANDREOPOULOU CN, Solomou EE, Kolorizos E, Diamantopoulos PT, et al
     Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.
     Ann Hematol. 2024 Jul 15. doi: 10.1007/s00277-024-05869.
     PubMed     Abstract available
     
     
     
220. CAO HY, Li HY, Cai WZ, Huang YH, et al
     Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements.
     Ann Hematol. 2024 Jul 11. doi: 10.1007/s00277-024-05868.
     PubMed     Abstract available
     
     
     
221. BUDAK B, Tukel EY, Turanli B, Kiraz Y, et al
     Correction to: Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities.
     Ann Hematol. 2024 Jul 11. doi: 10.1007/s00277-024-05881.
     PubMed    
     
     
     
222. LAIMON DN, Sakr DH, Atef B, Shaaban Y, et al
     Highlights of ophthalmological manifestations in newly diagnosed acute leukemia: a correlation with hematological parameters.
     Ann Hematol. 2024 Jul 10. doi: 10.1007/s00277-024-05861.
     PubMed     Abstract available
     
     
     
223. SINGH S, Lionel S, Jain H, Rajendra A, et al
     Treatment challenges and outcomes of older patients with acute myeloid leukemia from India.
     Ann Hematol. 2024 Jul 8. doi: 10.1007/s00277-024-05873.
     PubMed     Abstract available
     
     
     
224. ZHENG J, Zhao Y, Luo Y, Yu J, et al
     Impact of additional cytogenetic aberrations at diagnosis on prognosis of adults patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: a retrospective analysis.
     Ann Hematol. 2024 Jul 4. doi: 10.1007/s00277-024-05871.
     PubMed     Abstract available
     
     
     
225. WANG J, Mu M, Zhu J, Yang J, et al
     Adult acute leukemia patients with gram-negative bacteria bloodstream infection: Risk factors and outcomes of antibiotic-resistant bacteria.
     Ann Hematol. 2024 Jul 3. doi: 10.1007/s00277-024-05866.
     PubMed     Abstract available
     
     
     
226. CHEN R, Tao Q, Wu F, Zhai Z, et al
     DNT cells mediate resistance to CAR-T cells therapy in a pediatric patient with relapsed and refractory B-ALL.
     Ann Hematol. 2024;103:2551-2556.
     PubMed     Abstract available
     
     
     
227. PANDA D, Tejwani N, Pandey P, Mehta A, et al
     Myeloid sarcoma with RAM phenotype in an adult male presenting with CNS relapse; no longer a pediatric disease.
     Ann Hematol. 2024;103:2561-2563.
     PubMed    
     
     
     
228. CHEN Y, Chen Y, Wu Z, Li J, et al
     Nomogram predictive models for adult patients with acute lymphoblastic leukaemia based on real-world treatment outcomes.
     Ann Hematol. 2024;103:2393-2404.
     PubMed     Abstract available
     
     
     June 2024
229. GONG Y, Li Y, Chen X, Yang H, et al
     Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.
     Ann Hematol. 2024 Jun 27. doi: 10.1007/s00277-024-05856.
     PubMed     Abstract available
     
     
     
230. SHI Y, Chen X, Jin H, Zhu L, et al
     Correction to: Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.
     Ann Hematol. 2024 Jun 24. doi: 10.1007/s00277-024-05812.
     PubMed    
     
     
     
231. CAO X, Li Z, Zhang Y, Cui Q, et al
     Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation.
     Ann Hematol. 2024 Jun 20. doi: 10.1007/s00277-024-05849.
     PubMed     Abstract available
     
     
     
232. ZHOU K, Wang T, Pan L, Xu W, et al
     Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
     Ann Hematol. 2024 Jun 18. doi: 10.1007/s00277-024-05823.
     PubMed     Abstract available
     
     
     
233. WANG XZ, Gao XM, Wang JM, Cai H, et al
     Co-occurrence of Erdheim-Chester disease and clonally evolving acute myeloid leukemia with FLT3-ITD and PTPN11 mutations.
     Ann Hematol. 2024 Jun 15. doi: 10.1007/s00277-024-05842.
     PubMed     Abstract available
     
     
     
234. ABULIMITI M, Jia ZY, Wu Y, Yu J, et al
     Exploring and clinical validation of prognostic significance and therapeutic implications of copper homeostasis-related gene dysregulation in acute myeloid leukemia.
     Ann Hematol. 2024 Jun 15. doi: 10.1007/s00277-024-05841.
     PubMed     Abstract available
     
     
     
235. LI T, Wu P, Wang A, Chen M, et al
     A HNRNPC::RARB variant of acute promyelocytic leukemia with concurrent myeloid sarcoma of the spine.
     Ann Hematol. 2024 Jun 12. doi: 10.1007/s00277-024-05833.
     PubMed    
     
     
     
236. ZHANG Z, Fu C, Sun Y, Liu Y, et al
     High hyperdiploid karyotype with >/= 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China.
     Ann Hematol. 2024 Jun 8. doi: 10.1007/s00277-024-05834.
     PubMed     Abstract available
     
     
     
237. WEI D, Liang X, Huang M, Wang C, et al
     Targeting histone deacetylase 1 (HDAC1) in the bone marrow stromal cells revers imatinib resistance by modulating IL-6 in Ph + acute lymphoblastic leukemia.
     Ann Hematol. 2024 Jun 7. doi: 10.1007/s00277-024-05830.
     PubMed     Abstract available
     
     
     
238. BOUCHLA A, Sotiropoulou CD, Esteb C, Loupis T, et al
     Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy.
     Ann Hematol. 2024 Jun 6. doi: 10.1007/s00277-024-05785.
     PubMed     Abstract available
     
     
     
239. BUDAK B, Tukel EY, Turanli B, Kiraz Y, et al
     Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities.
     Ann Hematol. 2024 Jun 5. doi: 10.1007/s00277-024-05821.
     PubMed     Abstract available
     
     
     
240. ZHENG B, Geng Y, Li Y, Huang H, et al
     Specificity protein 1/3 regulate T-cell acute lymphoblastic leukemia cell proliferation and apoptosis through beta-catenin by acting as targets of miR-495-3p.
     Ann Hematol. 2024 Jun 3. doi: 10.1007/s00277-024-05764.
     PubMed     Abstract available
     
     
     
241. JAIN AG, Gesiotto Q, Ball S, Nodzon L, et al
     Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
     Ann Hematol. 2024;103:1941-1945.
     PubMed     Abstract available
     
     
     May 2024
242. LI Y, Zhang Q, Shao H
     Chemotherapy vs. "TKI + immunotherapy" in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene.
     Ann Hematol. 2024 May 29. doi: 10.1007/s00277-024-05816.
     PubMed    
     
     
     
243. WANG Q, Hu Y, Gao L, Zhang S, et al
     Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.
     Ann Hematol. 2024 May 28. doi: 10.1007/s00277-024-05810.
     PubMed     Abstract available
     
     
     
244. BRAUN A, Otoukesh S, Tinajero J, Marcucci G, et al
     Blinatumomab-induced macrophage activating syndrome (MAS) in adult with B-cell acute lymphoblastic leukemia (B-ALL).
     Ann Hematol. 2024 May 24. doi: 10.1007/s00277-024-05795.
     PubMed     Abstract available
     
     
     
245. IOVENE FR, Santinelli E, Armiento D, Sarlo C, et al
     Acute myeloid leukemia with paraneoplastic pemphigus successfully treated with a personalized antileukemic and immunosuppressive strategy.
     Ann Hematol. 2024 May 23. doi: 10.1007/s00277-024-05804.
     PubMed     Abstract available
     
     
     
246. CUI T, Li H, Zhou S, Li J, et al
     Impact of cladribine, cytarabine, and G-CSF (CLAG) as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia.
     Ann Hematol. 2024 May 17. doi: 10.1007/s00277-024-05791.
     PubMed     Abstract available
     
     
     
247. FONTECHA MB, Anadon MDR, Mercado Guzman V, Stanganelli C, et al
     Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.
     Ann Hematol. 2024 May 14. doi: 10.1007/s00277-024-05794.
     PubMed     Abstract available
     
     
     
248. TOLLE M, Gokbuget N, Habringer S, Keller U, et al
     Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia.
     Ann Hematol. 2024 May 11. doi: 10.1007/s00277-024-05789.
     PubMed    
     
     
     
249. SHI Y, Chen X, Jin H, Zhu L, et al
     Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.
     Ann Hematol. 2024 May 9. doi: 10.1007/s00277-024-05786.
     PubMed     Abstract available
     
     
     
250. MITROVIC-AJTIC O, Zivkovic E, Suboticki T, Diklic M, et al
     Inflammation mediated angiogenesis in chronic lymphocytic leukemia.
     Ann Hematol. 2024 May 7. doi: 10.1007/s00277-024-05781.
     PubMed     Abstract available
     
     
     
251. MENSHAWY NE, El-Ghonemy MS, Ebrahim MA, Fahmi MW, et al
     Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements.
     Ann Hematol. 2024 May 7. doi: 10.1007/s00277-024-05779.
     PubMed     Abstract available
     
     
     
252. FRANKE GN, Loewe G, Reiser M, Linde H, et al
     Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.
     Ann Hematol. 2024;103:1569-1575.
     PubMed     Abstract available
     
     
     
253. NISCOLA P, Gianfelici V, Giovannini M, Piccioni D, et al
     Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
     Ann Hematol. 2024;103:1787-1788.
     PubMed    
     
     
     
254. SHUMILOV E, Mazzeo P, Ghandili S, Kunstner A, et al
     Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
     Ann Hematol. 2024;103:1587-1599.
     PubMed     Abstract available
     
     
     April 2024
255. LIU Y, Liu Y, Chen P, Chen G, et al
     GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy.
     Ann Hematol. 2024 Apr 27. doi: 10.1007/s00277-024-05777.
     PubMed     Abstract available
     
     
     
256. TAZOE K, Harada N, Makuuchi Y, Kuno M, et al
     Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
     Ann Hematol. 2024 Apr 25. doi: 10.1007/s00277-024-05772.
     PubMed     Abstract available
     
     
     
257. BENCHIKH S, Charlene SSG, Bousfiha A, Razoki L, et al
     Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco.
     Ann Hematol. 2024 Apr 24. doi: 10.1007/s00277-024-05747.
     PubMed     Abstract available
     
     
     
258. THAU S, Poulsen CB, Brieghel C, Larsen MK, et al
     COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study.
     Ann Hematol. 2024 Apr 18. doi: 10.1007/s00277-024-05738.
     PubMed     Abstract available
     
     
     
259. JEBANESAN DZP, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, et al
     Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.
     Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05742.
     PubMed     Abstract available
     
     
     
260. LEOTTA S, Markovic U, Duminuco A, Mule A, et al
     Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
     Ann Hematol. 2024 Apr 13. doi: 10.1007/s00277-024-05725.
     PubMed     Abstract available
     
     
     
261. GU Z, Li F, Li M, Wang L, et al
     Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia/lymphoma in first complete remission: a single-center study.
     Ann Hematol. 2024 Apr 12. doi: 10.1007/s00277-024-05716.
     PubMed     Abstract available
     
     
     
262. LUO L, Jiao Y, Li Y, Yang P, et al
     Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.
     Ann Hematol. 2024 Apr 6. doi: 10.1007/s00277-024-05719.
     PubMed     Abstract available
     
     
     
263. PEREZ-LAMAS L, de Paz Arias R, Diaz RMA, Montero LFC, et al
     Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
     Ann Hematol. 2024 Apr 3. doi: 10.1007/s00277-024-05662.
     PubMed     Abstract available
     
     
     
264. LIU S, Cui Q, Li M, Li Z, et al
     Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
     Ann Hematol. 2024;103:1397-1402.
     PubMed     Abstract available
     
     
     
265. REN Y, Liu F, Chen X, Zhang X, et al
     Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
     Ann Hematol. 2024;103:1345-1351.
     PubMed     Abstract available
     
     
     
266. LUCERO J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, et al
     Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
     Ann Hematol. 2024;103:1187-1196.
     PubMed     Abstract available
     
     
     
267. WANG J, Zhu H, Miao K
     Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.
     Ann Hematol. 2024 Apr 1. doi: 10.1007/s00277-024-05714.
     PubMed     Abstract available
     
     
     March 2024
268. CHEN Y, Pan M, Chen L, Peng M, et al
     Correction to: Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
     Ann Hematol. 2024 Mar 27. doi: 10.1007/s00277-024-05675.
     PubMed    
     
     
     
269. WU CY, Yeh CM, Tsai CK, Liu CJ, et al
     The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients.
     Ann Hematol. 2024 Mar 26. doi: 10.1007/s00277-024-05616.
     PubMed     Abstract available
     
     
     
270. CAI X, Liu Y, Li H, Que Y, et al
     XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
     Ann Hematol. 2024 Mar 23. doi: 10.1007/s00277-024-05706.
     PubMed     Abstract available
     
     
     
271. KUROSAWA S, Yokota T, Takada Y, Okubo S, et al
     Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.
     Ann Hematol. 2024 Mar 21. doi: 10.1007/s00277-024-05721.
     PubMed    
     
     
     
272. HUANG XT, Wang CJ, Gao C, Xue TL, et al
     Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.
     Ann Hematol. 2024 Mar 18. doi: 10.1007/s00277-024-05687.
     PubMed     Abstract available
     
     
     
273. OU J, Deng S, Ding C, Cai Z, et al
     Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia.
     Ann Hematol. 2024 Mar 7. doi: 10.1007/s00277-024-05681.
     PubMed     Abstract available
     
     
     
274. RORVIK SD, Torkildsen S, Bruserud O, Tvedt THA, et al
     Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.
     Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05680.
     PubMed     Abstract available
     
     
     
275. DARTIGEAS C, Quinquenel A, Ysebaert L, Dilhuydy MS, et al
     Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
     Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05666.
     PubMed     Abstract available
     
     
     
276. WU X, Ma X, Song T, Liu J, et al
     The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping.
     Ann Hematol. 2024;103:917-933.
     PubMed     Abstract available
     
     
     
277. KENNEDY A, Patel S, Ramanathan M, Gerber J, et al
     Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.
     Ann Hematol. 2024;103:1031-1033.
     PubMed    
     
     
     
278. KRECAK I, Cubric E, Smolic J, Vrbicic B, et al
     Small lymphocytic lymphoma infiltrating gastrointestinal tract and mimicking inflammatory bowel disease, successfully treated with acalabrutinib.
     Ann Hematol. 2024;103:1021-1023.
     PubMed    
     
     
     
279. PALANI HK, Ganesan S, Balasundaram N, Venkatraman A, et al
     Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia.
     Ann Hematol. 2024 Mar 1. doi: 10.1007/s00277-024-05673.
     PubMed    
     
     
     February 2024
280. SCHWANER I, Kuhn T, Losem C, Wolff T, et al
     Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
     Ann Hematol. 2024 Feb 29. doi: 10.1007/s00277-024-05638.
     PubMed     Abstract available
     
     
     
281. CHEN Y, Zheng J, Weng Y, Wu Z, et al
     Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.
     Ann Hematol. 2024 Feb 27. doi: 10.1007/s00277-024-05679.
     PubMed     Abstract available
     
     
     
282. TERAMOTO M, Tamaki H, Kaida K, Samori M, et al
     Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis.
     Ann Hematol. 2024 Feb 23. doi: 10.1007/s00277-024-05654.
     PubMed     Abstract available
     
     
     
283. WANG X, Zhang Y, Xue S
     Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
     Ann Hematol. 2024 Feb 21. doi: 10.1007/s00277-023-05601.
     PubMed     Abstract available
     
     
     
284. GOTO T, Nakamura N, Suzaki T, Shimazu R, et al
     A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration.
     Ann Hematol. 2024 Feb 20. doi: 10.1007/s00277-024-05660.
     PubMed    
     
     
     
285. LI X, Zhou J, Li J, Zhu X, et al
     Effectiveness and safety of blinatumomab for pediatric B cell acute lymphoblastic leukemia with Loeffler's endocarditis.
     Ann Hematol. 2024 Feb 17. doi: 10.1007/s00277-024-05656.
     PubMed    
     
     
     
286. ZHAO L, Yang J, Chen M, Xiang X, et al
     Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
     Ann Hematol. 2024 Feb 8. doi: 10.1007/s00277-024-05646.
     PubMed     Abstract available
     
     
     
287. FONTANA D, Zambrotta GPM, Scannella A, Piazza R, et al
     Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.
     Ann Hematol. 2024 Feb 7. doi: 10.1007/s00277-024-05649.
     PubMed     Abstract available
     
     
     
288. SCHLOSSER P, Schiwitza A, Klaus J, Hieke-Schulz S, et al
     Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia.
     Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05627.
     PubMed     Abstract available
     
     
     
289. SUAREZ EU, Piris MA, Rodriguez-Pinilla SM, Garcia JF, et al
     Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage.
     Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05647.
     PubMed    
     
     
     
290. WANG J, Zhang H, Zhang R
     BRCA2 germline mutation in familial leukaemia with familial breast cancer: a case report.
     Ann Hematol. 2024;103:685-687.
     PubMed    
     
     
     
291. BRUNNER A, Thalhammer-Thurner GC, Willenbacher W, Haun M, et al
     In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.
     Ann Hematol. 2024;103:553-563.
     PubMed     Abstract available
     
     
     
292. FERNANDEZ-LUIS S, Gomez Lamas D, Cerezo Martin JM, Mora Barrios JM, et al
     Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age.
     Ann Hematol. 2024;103:583-591.
     PubMed     Abstract available
     
     
     January 2024
293. CHEN Y, Pan M, Chen L, Peng M, et al
     Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
     Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05629.
     PubMed     Abstract available
     
     
     
294. CUI J, Zhao M, Liu W, Hong M, et al
     Effect of low skeletal muscle mass on NK cells in patients with acute myeloid leukemia and its correlation with prognosis.
     Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05645.
     PubMed     Abstract available
     
     
     
295. LIU Y, Ma Z
     Leukemia and mitophagy: a novel perspective for understanding oncogenesis and resistance.
     Ann Hematol. 2024 Jan 29. doi: 10.1007/s00277-024-05635.
     PubMed     Abstract available
     
     
     
296. GABELLIER L, Peterlin P, Thepot S, Hicheri Y, et al
     Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
     Ann Hematol. 2024 Jan 26. doi: 10.1007/s00277-024-05623.
     PubMed     Abstract available
     
     
     
297. CHATTOPADHYAY S, Lionel S, Selvarajan S, Devasia AJ, et al
     Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival.
     Ann Hematol. 2024 Jan 20. doi: 10.1007/s00277-024-05621.
     PubMed     Abstract available
     
     
     
298. MURRU R, Galitzia A, Barabino L, Presicci R, et al
     Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis.
     Ann Hematol. 2024 Jan 18. doi: 10.1007/s00277-024-05625.
     PubMed     Abstract available
     
     
     
299. ZHAO Y, Zhang X, Zhang M, Guo R, et al
     Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
     Ann Hematol. 2024 Jan 12. doi: 10.1007/s00277-024-05617.
     PubMed     Abstract available
     
     
     
300. DEREME J, Voruz S, Solly F, Schoumans J, et al
     Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript.
     Ann Hematol. 2024 Jan 9. doi: 10.1007/s00277-023-05600.
     PubMed    
     
     
     
301. SONG J, Li W, Bai Y, Zhou P, et al
     A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
     Ann Hematol. 2024 Jan 6. doi: 10.1007/s00277-023-05594.
     PubMed     Abstract available
     
     
     
302. PERRUSO LL, Velloso E, Rocha V, Rego EM, et al
     Patterns and prognostic impact of CNS infiltration in adults with newly diagnosed acute lymphoblastic leukemia.
     Ann Hematol. 2024 Jan 5. doi: 10.1007/s00277-023-05609.
     PubMed     Abstract available
     
     
     
303. WANG R, Xu Y, Wang B, Wang H, et al
     Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
     Ann Hematol. 2024;103:61-71.
     PubMed     Abstract available
     
     
     
304. AL BARASHDI MAS, Ali A, McMullin MF, Mills K, et al
     CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy.
     Ann Hematol. 2024;103:73-88.
     PubMed     Abstract available
     
     
     December 2023
305. HUANG P, Chang H, Zhang R, Wu Y, et al
     Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia.
     Ann Hematol. 2023 Dec 28. doi: 10.1007/s00277-023-05593.
     PubMed     Abstract available
     
     
     
306. PAN B, Xu Z, Du K, Gao R, et al
     Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapy.
     Ann Hematol. 2023 Dec 27. doi: 10.1007/s00277-023-05590.
     PubMed     Abstract available
     
     
     
307. SOBAS M, Knopinska-Posluszny W, Piatkowska-Jakubas B, Garcia-Alvarez F, et al
     Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
     Ann Hematol. 2023 Dec 19. doi: 10.1007/s00277-023-05582.
     PubMed     Abstract available
     
     
     
308. PARK T, Byun JM, Shin DY, Koh Y, et al
     Clinical characteristics and treatment outcomes of Asian patients with T-cell large granular lymphocytic Leukemia: a single-center analysis of 67 cases.
     Ann Hematol. 2023 Dec 8. doi: 10.1007/s00277-023-05575.
     PubMed     Abstract available
     
     
     
309. ZHENG X, Gao H, Lu N, Wang M, et al
     Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
     Ann Hematol. 2023;102:3603-3611.
     PubMed     Abstract available
     
     
     
310. HU J, Zhao J, Wang C, Jia M, et al
     Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation.
     Ann Hematol. 2023;102:3593-3601.
     PubMed     Abstract available
     
     
     
311. ANDERSEN M JR, Bindal P, Michaels P, Elavalakanar P, et al
     Clonal myeloid disorders following CAR T-cell therapy.
     Ann Hematol. 2023;102:3643-3645.
     PubMed    
     
     
     
312. BEWERSDORF JP, Shallis RM, Sharon E, Park S, et al
     A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
     Ann Hematol. 2023 Dec 1. doi: 10.1007/s00277-023-05552.
     PubMed     Abstract available
     
     
     November 2023
313. MARRA JD, Frioni F, Minnella G, Rossi M, et al
     Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management.
     Ann Hematol. 2023 Nov 29. doi: 10.1007/s00277-023-05561.
     PubMed    
     
     
     
314. MULAS O, Abruzzese E, Luciano L, Iurlo A, et al
     The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
     Ann Hematol. 2023 Nov 28. doi: 10.1007/s00277-023-05556.
     PubMed     Abstract available
     
     
     
315. ISHIDA H, Arakawa Y, Hasegawa D, Usami I, et al
     Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia.
     Ann Hematol. 2023 Nov 25. doi: 10.1007/s00277-023-05557.
     PubMed     Abstract available
     
     
     
316. FISCHER D, Toenges R, Kiil K, Michalik S, et al
     Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
     Ann Hematol. 2023 Nov 24. doi: 10.1007/s00277-023-05495.
     PubMed     Abstract available
     
     
     
317. SHANG CY, Bei LY, Wu JZ, Sheng HR, et al
     NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia.
     Ann Hematol. 2023 Nov 23. doi: 10.1007/s00277-023-05554.
     PubMed     Abstract available
     
     
     
318. GAO J, Han S, Deng B, Deng Y, et al
     Research progress of additional pathogenic mutations in chronic neutrophilic leukemia.
     Ann Hematol. 2023 Nov 22. doi: 10.1007/s00277-023-05550.
     PubMed     Abstract available
     
     
     
319. TIAN J, Wei A, Wang B, Yang J, et al
     Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia.
     Ann Hematol. 2023 Nov 22. doi: 10.1007/s00277-023-05506.
     PubMed     Abstract available
     
     
     
320. LAP CJ, Abrahim MS, Nassereddine S
     Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.
     Ann Hematol. 2023 Nov 17. doi: 10.1007/s00277-023-05545.
     PubMed     Abstract available
     
     
     
321. CHEN B, Zhao Y, Xu S, Jiang F, et al
     USF2 promotes autophagy and proliferation in chronic lymphocytic leukemia by inhibiting STUB1-induced NFAT5 ubiquitination.
     Ann Hematol. 2023 Nov 10. doi: 10.1007/s00277-023-05522.
     PubMed     Abstract available
     
     
     
322. LUCIJANIC M, Tomasovic-Loncaric C, Stoos-Veic T, De Both T, et al
     Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.
     Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05529.
     PubMed    
     
     
     
323. AHMED HA, Nafady A, Ahmed EH, Hassan EEN, et al
     CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia.
     Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05540.
     PubMed     Abstract available
     
     
     
324. FAN S, Wang L, Lu Y, Li Z, et al
     Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.
     Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05519.
     PubMed     Abstract available
     
     
     
325. DE OLIVEIRA FERNANDES JUNIOR I, Arcuri LJ
     Myeloablative or reduced-intensity/non-myeloablative hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in adults older than 40 years old - a secondary analysis of a CIBMTR database.
     Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05532.
     PubMed     Abstract available
     
     
     
326. BABAKHANLOU R, Nader ME, Alvarado Y
     Correction to: A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia.
     Ann Hematol. 2023 Nov 3. doi: 10.1007/s00277-023-05524.
     PubMed    
     
     
     
327. HUSSAN SS, Ali MS, Fatima M, Altaf M, et al
     Epigenetically dysregulated NOTCH-Delta-HES signaling cascade can serve as a subtype classifier for acute lymphoblastic leukemia.
     Ann Hematol. 2023 Nov 3. doi: 10.1007/s00277-023-05515.
     PubMed     Abstract available
     
     
     
328. HUANG X, Li T, Zhang Y, Gao X, et al
     Hemophagocytosis by multinucleated leukemic blasts, basophilia, and micromegakaryocytes in AML with TLS::ERG.
     Ann Hematol. 2023;102:3279-3281.
     PubMed    
     
     
     
329. PERRONE S, Imperatore S, Sucato G, Notarianni E, et al
     Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect.
     Ann Hematol. 2023;102:3025-3030.
     PubMed     Abstract available
     
     
     
330. HEGDE NC, Kumar A, Kaundal S, Saha L, et al
     Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia.
     Ann Hematol. 2023;102:3125-3132.
     PubMed     Abstract available
     
     
     October 2023
331. SAVANI S, Chennapragada SS, Ramphul K, Dandwani M, et al
     Factors associated with inpatient mortality during daunorubicin and cytarabine induction in adults with acute myeloid leukemia-a national inpatient sample analysis.
     Ann Hematol. 2023 Oct 27. doi: 10.1007/s00277-023-05505.
     PubMed    
     
     
     
332. TANG H, Chen Y, Zhang N, Deng J, et al
     Higher expression of programmed cell death 4 (PDCD4) in acute myeloid leukemia is associated with better prognosis after chemotherapy.
     Ann Hematol. 2023 Oct 25. doi: 10.1007/s00277-023-05516.
     PubMed     Abstract available
     
     
     
333. CUI Y, Peng H
     Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia.
     Ann Hematol. 2023 Oct 21. doi: 10.1007/s00277-023-05489.
     PubMed    
     
     
     
334. FEI X, Zhang W, Gu J, Yang F, et al
     CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
     Ann Hematol. 2023 Oct 17. doi: 10.1007/s00277-023-05502.
     PubMed     Abstract available
     
     
     
335. YIN S, Zheng X, Zhang W, Zhao H, et al
     Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
     Ann Hematol. 2023 Oct 16. doi: 10.1007/s00277-023-05486.
     PubMed     Abstract available
     
     
     
336. EISENACH S, Zinke J, Bramer D, Hartinger S, et al
     Detection of a rare JAK2(exon13InDel)-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Loffler endocarditis.
     Ann Hematol. 2023 Oct 16. doi: 10.1007/s00277-023-05490.
     PubMed    
     
     
     
337. CREMER A, Enssle JC, Pfaff S, Kouidri K, et al
     Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
     Ann Hematol. 2023;102:2903-2908.
     PubMed     Abstract available
     
     
     
338. MARTINO G, Cimino G, Caridi M, Perta G, et al
     One disease, two faces: clonally-related AML and MPDCP with skin involvement.
     Ann Hematol. 2023;102:2969-2971.
     PubMed    
     
     
     September 2023
339. XU Y, Gao H, Li H
     The gut microbiome: an important factor influencing therapy for pediatric acute lymphoblastic leukemia.
     Ann Hematol. 2023 Sep 29. doi: 10.1007/s00277-023-05480.
     PubMed     Abstract available
     
     
     
340. PEREIRA MP, Herrity E, Kim DDH
     TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
     Ann Hematol. 2023 Sep 28. doi: 10.1007/s00277-023-05462.
     PubMed     Abstract available
     
     
     
341. ZOU D, Lv M, Chen Y, Niu T, et al
     Down-regulation of Musashi-2 exerts antileukemic effects on acute lymphoblastic leukemia cells and increases sensitivity to dexamethasone.
     Ann Hematol. 2023 Sep 26. doi: 10.1007/s00277-023-05468.
     PubMed     Abstract available
     
     
     
342. CANDAN O, Demirtas D, Yanik AM, Atagunduz I, et al
     The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia.
     Ann Hematol. 2023 Sep 20. doi: 10.1007/s00277-023-05456.
     PubMed    
     
     
     
343. LIN Q, Ye P, Wang T, Lu Y, et al
     Successful use of venetoclax combined with azacitidine in isolated extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report.
     Ann Hematol. 2023 Sep 20. doi: 10.1007/s00277-023-05401.
     PubMed    
     
     
     
344. LI H, Hou J, Fu Y, Zhao Y, et al
     miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
     Ann Hematol. 2023 Sep 19. doi: 10.1007/s00277-023-05441.
     PubMed     Abstract available
     
     
     
345. WENG G, Huang J, He X, Xue T, et al
     Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
     Ann Hematol. 2023 Sep 18. doi: 10.1007/s00277-023-05452.
     PubMed     Abstract available
     
     
     
346. BABAKHANLOU R, Ellie-Nader M, Alvarado Y
     A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia.
     Ann Hematol. 2023 Sep 15. doi: 10.1007/s00277-023-05433.
     PubMed     Abstract available
     
     
     
347. CROUCHER PJP, Ridinger M, Becker PS, Lin TL, et al
     Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
     Ann Hematol. 2023 Sep 13. doi: 10.1007/s00277-023-05442.
     PubMed     Abstract available
     
     
     
348. JIANG S, Lu X, Wei R, Zhang A, et al
     Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study.
     Ann Hematol. 2023 Sep 8. doi: 10.1007/s00277-023-05406.
     PubMed     Abstract available
     
     
     
349. WANG Q, Liang Z, Ren H, Dong Y, et al
     Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.
     Ann Hematol. 2023 Sep 4. doi: 10.1007/s00277-023-05429.
     PubMed     Abstract available
     
     
     
350. LIU Y, Chen P, Chen G, Chen X, et al
     E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
     Ann Hematol. 2023 Sep 4. doi: 10.1007/s00277-023-05431.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.